Skip to content

X4 Pharmaceuticals, Inc

XFOR· NasdaqCore metricsCIK 1501697

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -1.40%
Market cap
$324.21M
102.11M shares
Filings
821
$2.88M
Q3 2026+1,273.2% FY25 yoy
-$20.20M
Q3 2026N/M FY25 yoy
-$19.99M
Q3 2026N/M FY25 yoy
-$85.62M
FY 2025derivedN/M FY25 yoy
-$0.16
Q3 2026N/M FY25 yoy
$185.80M
Q3 2026+289.7% FY25 yoy
$324.21M
—
19.1×
2.3×
—
—

Twelve months to Sep 30, 2026 · derived

Price

$3.189.67%$0.34past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of record

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$35.11MFY 2025
$35.11M0FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$35,113,000reported
FY 20242024-12-31$2,557,000reported
FY 20232023-12-31$0reported
FY 20222022-12-31$0reported
FY 20212021-12-31$0reported
FY 20202020-12-31$3,000,000reported
FY 20192019-12-31$0reported
FY 20182018-12-31$0 revisedreported

Capital returns

Dividends and buybacks · FY2019 to FY2023
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2023—$0.00$0.00—167.94M sh+37.4%—
FY2022—$0.00$0.00—122.21M sh+296.7%—
FY2021—$2.00M$2.00M—30.81M sh+77.2%—
FY2020—$0.00$0.00—17.38M sh+7.7%—
FY2019—$0.00$0.00—16.13M sh+10.2%—

Segments

Long-lived assets by Geography, FY2023 to FY2024FY2023UNITED STATES · FY2023 · $4.30MAUSTRIA · FY2023 · $2.10MFY2024UNITED STATES · FY2024 · $3.20MAUSTRIA · FY2024 · $1.70M
LineFY2024ShareChange
UNITED STATES$3.20M412%−25.6%
AUSTRIA$1.70M219%−19.0%
Total$776.00K

From the 10-K filed Mar 26, 2025XFOR

Biological products, except diagnostic substances

X4 Pharmaceuticals, Inc is the 51st largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

X4 Pharmaceuticals, Inc · CIK 1501697 · Engraved from SEC EDGAR